Compare CDNA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDNA | INBX |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 999.7M |
| IPO Year | 2007 | 2024 |
| Metric | CDNA | INBX |
|---|---|---|
| Price | $21.74 | $100.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $28.00 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 652.5K | 489.3K |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $48,324,000.00 | $1,300,000.00 |
| Revenue This Year | $16.01 | N/A |
| Revenue Next Year | $11.31 | N/A |
| P/E Ratio | $429.80 | ★ N/A |
| Revenue Growth | 18.93 | ★ 550.00 |
| 52 Week Low | $10.96 | $12.80 |
| 52 Week High | $23.24 | $155.29 |
| Indicator | CDNA | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 45.50 |
| Support Level | $15.80 | $99.20 |
| Resistance Level | $22.89 | $153.14 |
| Average True Range (ATR) | 1.00 | 13.75 |
| MACD | -0.06 | -3.93 |
| Stochastic Oscillator | 76.54 | 8.06 |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.